# Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

> **NCT05765877** · PHASE2 · RECRUITING · sponsor: **Pingping Song** · enrollment: 26 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer(NSCLC)

## Interventions

- **DRUG:** WX-0593 Tablets

## Key facts

- **NCT ID:** NCT05765877
- **Lead sponsor:** Pingping Song
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2027-03
- **Final completion:** 2029-03
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05765877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05765877, "Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05765877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*